Grzegorz Stańko


Introduction: Colorectal cancer is one of the most common malignancies. It is the second most common cause of cancer death in men and the third most common in women. The aetiology of colorectal cancer is multifactorial, complicated, and remains the subject of many studies. It has been estimated that only 15–30% cases of colorectal cancer are hereditary. The aim of the study was to determine the relationship between the C3435T and G2677T/A polymorphisms of the MDR1 gene and the risk of developing colorectal cancer.

Materials and methods: The study group comprised 47 women and 60 men with colorectal cancer. The age of patients was 47–83 years. In each case the diagnosis of colorectal cancer was confirmed by histopathological examination. The control group comprised 110 subjects without malignant colorectal cancer. Genetic analysis was carried out using PCR -RFLP.

Results: A relationship between the presence of CT and TT genotypes of C3435T MDR1 gene polymorphism and onset of colorectal cancer at a younger age was found. No correlation between C3435T or G2677T/A MDR1 gene polymorphism and other clinical parameters was identified.

Conclusions: Further studies are necessary on a significantly greater number of genes and their polymorphisms. Findings from this study may be used as a part of polygenic analysis aimed at explaining the complicated processes responsible for the onset and development of colorectal cancer.


colorectal cancer; polymorphism; MDR1; P–glycoprotein

Full Text:

PDF (Język Polski)


Didkowska J., Wojciechowska U., Zatoński W.: Nowotwory złośliwe w Polsce w 2009 roku. Krajowy Rejestr Nowotworów. Centrum Onkologii, Warszawa 2009.

Katballe N., Christensen M., Wikman F.P., Orntoft T.F., Laurberg S.: Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut. 2002, 50, 43–51.

Vasen H.F.: Clinical description of the Lynch syndrome [hereditary nonpolyposis colorectal cancer (HNPCC)]. Fam Cancer. 2005, 4 (3), 219–225.

Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M.: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999, 39, 361–398.

Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., Willingham M.C.: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987, 84 (21), 7735–7738.

Johnstone R.W., Ruefli A.A., Smyth M.J.: Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci. 2000, 25 (1), 1–6.

Maeda K., Sugiyama Y.: Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008, 23 (4), 223–235.

Dudarewicz M., Barańska M., Rychlik-Sych M., Trzciński R., Dziki A.: C3435T polymorphism of the ABCB1/MDR1 gene encoding P-glycoprotein in patients with inflammatory bowel disease in a Polish population. Pharmacol Rep. 2012, 64, 343–350.

Kerb R.: Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006, 234, 4–33.

Andersen V., Ostergaard M., Christensen J., Overvad K., Tjonneland A., Vogel U.: Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study. BMC Cancer. 2009, 9, 407–418.

Campa D., Sainz J., Pardini B., Vodickova L., Naccarati A., Rudolph A. et al.: A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer. PLoS One. 2012, 7 (3), e32784.

Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V. et al.: A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007, 315 (5811), 525–528.

Mickley L.A., Lee J.S., Weng Z., Zhan Z., Alvarez M., Wilson W. et al.: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998, 91 (5), 1749–1756.

Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M. et al.: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001, 69, 169–174.

Bogacz A., Mrozikiewicz P.M., Deka-Pawlik D., Seremak-Mrozikiewicz A., Bartkowiak-Wieczorek J., Barlik M. et al.: Frequency of G2677T/A and C3435T polymorphisms of MDR1 gene in preeclamptic women. Ginekol Pol. 2013, 84, 781–787.

Petrova D.T., Nedeva P., Maslyankov S., Toshev S., Yaramov N., Atanasova S. et al.: No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. J Cancer Res Clin Oncol. 2008, 134, 317–322.

Kurzawski M., Droździk M., Suchy J., Kurzawski G., Białecka M., Górnik W. et al.: Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur J Clin Pharmacol. 2005, 61, 389–394.

Osswald E., Johne A., Laschinski G., Arjomand 18.-Nahad F.,-Nahad F., Malzahn U., Kirchheiner J. et al.: Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers. Eur J Clin Pharmacol. 2007, 63, 9–16.

Wang J., Wang B., Bi J., Li K., Di J.: MDR1 gene C3435T polymorphism and cancer risk: a meta-analysis of 34 case-control studies. J Cancer Res Clin Oncol. 2012, 138, 979–989.

Sheng X., Zhang L., Tong N., Luo D., Wang M., Xu M. et al.: MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies. Mol Biol Rep. 2012, 39, 7237–7249.

Komoto C., Nakamura T., Sakaeda T., Kroetz D.L., Yamada T., Omatsu H. et al.: MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer. Drug Metab Pharmacokinet. 2006, 21, 126–132.

De Iudicibus S., De Pellegrin A., Stocco G., Bartoli F., Bussani R., Decorti G.: ABCB1 gene polymorphisms and expression of P-glycoprotein and long-term prognosis in colorectal cancer. Anticancer Res. 2008, 28, 3921–3928.


Copyright (c) 2015 Grzegorz Stańko

License URL: